Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.17 is 94% above its 5-year average of -2.69, near the high end of its 5-year range (-3.26–-0.17).
92.83% above its 12-month average of -2.37.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 1.09.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.17
EARNINGS PER SHARE (EPS) AVG TTM
-2.37
EARNINGS PER SHARE (EPS) AVG 3Y
-2.73
EARNINGS PER SHARE (EPS) AVG 5Y
-2.69
EARNINGS PER SHARE (EPS) AVG 10Y
-3.71
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+92.83%
CURRENT VS 3Y AVG
+93.77%
CURRENT VS 5Y AVG
+93.67%
CURRENT VS 10Y AVG
+95.41%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Rocket Pharmaceuticals, Inc.
Market Cap
$271.89M
Earnings Per Share (EPS)
-0.17
TTM Avg
-2.37
3Y Avg
-2.73
5Y Avg
-2.69
Market Cap
$270.68M
Earnings Per Share (EPS)
-0.86
TTM Avg
-1.73
3Y Avg
-3.85
5Y Avg
-2.38
Market Cap
$269.83M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.40
3Y Avg
-1.83
5Y Avg
-1.95
Market Cap
$269.11M
Earnings Per Share (EPS)
-4.63
TTM Avg
-2.03
3Y Avg
-0.98
5Y Avg
-0.48
Market Cap
$268.47M
Earnings Per Share (EPS)
-1.30
TTM Avg
-1.74
3Y Avg
-1.50
5Y Avg
-1.50
Market Cap
$267.65M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.37M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.82
3Y Avg
-2.37
5Y Avg
-2.68
Market Cap
$265.65M
Earnings Per Share (EPS)
-0.93
TTM Avg
-0.92
3Y Avg
-0.85
5Y Avg
-0.65
Market Cap
$264.34M
Earnings Per Share (EPS)
-0.53
TTM Avg
-5.25
3Y Avg
-13.51
5Y Avg
-397.38
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | $271.89M | -0.17 | -2.37 | -2.73 | -2.69 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.68M | -0.86 | -1.73 | -3.85 | -2.38 |
| Fate Therapeutics, Inc. (FATE)vs › | $269.83M | -1.05 | -1.40 | -1.83 | -1.95 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $269.11M | -4.63 | -2.03 | -0.98 | -0.48 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $268.47M | -1.30 | -1.74 | -1.50 | -1.50 |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.65M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $267.37M | -0.48 | -0.82 | -2.37 | -2.68 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $265.65M | -0.93 | -0.92 | -0.85 | -0.65 |
| Palisade Bio, Inc. (PALI)vs › | $264.34M | -0.53 | -5.25 | -13.51 | -397.38 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $261.58M | -3.74 | -2.75 | -2.51 | -2.60 |
Trailing EPS (TTM)
$-0.17
Forward EPS (Est.)
$-0.13
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.01 |
| 2024-12-31 | -2.73 |
| 2023-12-31 | -2.92 |
| 2022-12-31 | -3.26 |
| 2021-12-31 | -2.68 |
| 2020-12-31 | -2.52 |
| 2019-12-31 | -1.70 |
| 2018-12-31 | -1.89 |
| 2017-12-31 | -4.36 |
| 2016-12-31 | -6.41 |
| 2015-12-31 | -10.29 |
| 2014-12-31 | -4.53 |
| 2013-12-31 | -3.62 |
| 2012-12-31 | -2.88 |
